Evidence map›Paper›PMID 42390562›Full record

SynthesisEuropean journal of nuclear medicine and molecular imaging2026

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

Alessandro Bertocchi, Fabio De Vincenzo, Matteo Perrino, Nadia Cordua, Priscilla Guglielmo, Marta Aliprandi, Luigi Giovanni Cecchi, Antonio Federico, Antonella Panzardi, Armando Santoro and 2 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alessandro Bertocchi *Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy. alessandro.bertocchi@st.hunimed.eu.ORCID http://orcid.org/0009-0008-9708-3629
Fabio De Vincenzo *Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy. fabio.de_vincenzo@humanitas.it.ORCID http://orcid.org/0000-0002-1811-7050
Matteo PerrinoMedical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.ORCID http://orcid.org/0000-0001-9864-8814
Nadia CorduaDepartment of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.ORCID http://orcid.org/0009-0006-6968-270X
Priscilla GuglielmoDepartment of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.ORCID http://orcid.org/0000-0001-9150-4367
Marta AliprandiDepartment of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.
Luigi Giovanni CecchiDepartment of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.ORCID http://orcid.org/0009-0008-4362-9892
Antonio FedericoDepartment of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.ORCID http://orcid.org/0009-0006-1278-9223
Antonella PanzardiDepartment of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.
Armando SantoroMedical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.ORCID http://orcid.org/0000-0003-1709-9492
Laura Evangelista *Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.ORCID http://orcid.org/0000-0002-5955-9488
Paolo Andrea Zucali *Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.ORCID http://orcid.org/0000-0002-2274-1702

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTesticular germ cell tumours (TGCTs) are the most common malignancy in young adult males. After chemotherapy, the evaluation of residual masses is critical. However, the current standard imaging modality, [

objectivesThis systematic review aims to explore and evaluate novel PET tracers that could improve diagnostic accuracy in TGCTs, especially in post-chemotherapy settings.

methodsA comprehensive literature search was conducted on PubMed and Scopus through December 2025, using terms including "testicular," "germ cell tumour," "PET scan," and "novel." Studies focusing solely on [

resultsA total of 17 studies met the inclusion criteria. Emerging PET tracers evaluated include [

conclusionsNovel PET tracers represent a promising avenue to refine TGCT management. αvβ3-integrin and ghrelin-based tracers are particularly noteworthy for their potential to guide decision-making after chemotherapy. However, further clinical validation is required before routine implementation. These innovations could significantly reduce overtreatment and enhance personalized care in TGCT patients.

Indexed as

Neoplasms, Germ Cell and EmbryonalPositron-Emission TomographyTesticular NeoplasmsAnimalsHumansMaleNeoplasm MetastasisNeoplasm, ResidualRadioactive TracersRadioactive TracersPET scanPET tracerResidual massesTesticular germ cell tumours

Identifiers

PMID42390562
PMCPMC13633289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.